Ensysce Biosciences, Inc. (ENSC)
0.4811
+0.01
(+1.71%)
USD |
NASDAQ |
Sep 09, 11:40
Ensysce Biosciences Enterprise Value : 6.867M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 6.867M |
| September 04, 2026 | 6.586M |
| September 03, 2026 | 6.331M |
| September 02, 2026 | 6.376M |
| September 01, 2026 | 5.489M |
| August 31, 2026 | 5.564M |
| August 28, 2026 | 5.680M |
| August 27, 2026 | 5.666M |
| August 26, 2026 | 5.877M |
| August 25, 2026 | 5.731M |
| August 24, 2026 | 5.049M |
| August 21, 2026 | 5.249M |
| August 20, 2026 | 5.322M |
| August 19, 2026 | 5.487M |
| August 18, 2026 | 5.439M |
| August 17, 2026 | 5.302M |
| August 14, 2026 | 5.680M |
| August 13, 2026 | 4.846M |
| August 12, 2026 | 5.661M |
| August 11, 2026 | 6.015M |
| August 10, 2026 | 6.177M |
| August 07, 2026 | 7.632M |
| August 06, 2026 | 7.699M |
| August 05, 2026 | 5.065M |
| August 04, 2026 | 5.426M |
| Date | Value |
|---|---|
| August 03, 2026 | 3.736M |
| July 31, 2026 | 3.297M |
| July 30, 2026 | 3.362M |
| July 29, 2026 | 3.293M |
| July 28, 2026 | 3.264M |
| July 27, 2026 | 3.436M |
| July 24, 2026 | 3.433M |
| July 23, 2026 | 3.615M |
| July 22, 2026 | 3.792M |
| July 21, 2026 | 3.837M |
| July 20, 2026 | 3.568M |
| July 17, 2026 | 3.780M |
| July 16, 2026 | 3.692M |
| July 15, 2026 | 3.920M |
| July 14, 2026 | 3.938M |
| July 13, 2026 | 3.662M |
| July 10, 2026 | 3.571M |
| July 09, 2026 | 3.686M |
| July 08, 2026 | 3.654M |
| July 07, 2026 | 3.670M |
| July 06, 2026 | 3.975M |
| July 02, 2026 | 3.800M |
| July 01, 2026 | 4.087M |
| June 30, 2026 | 3.897M |
| June 29, 2026 | 1.894M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.79B |
| Oncolytics Biotech, Inc. | 96.67M |
| Sangamo Therapeutics, Inc. | 58.40M |
| Sarepta Therapeutics, Inc. | 2.469B |
| Anixa Biosciences, Inc. | 83.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.571M |
| Revenue (Quarterly) | 1.164M |
| Total Expenses (Quarterly) | 3.735M |
| EPS Diluted (Quarterly) | -0.1972 |
| Gross Profit Margin (Quarterly) | 99.44% |
| Profit Margin (Quarterly) | -220.8% |
| Earnings Yield | -573.5% |
| Normalized Earnings Yield | -573.60 |